Zaditen 1 - Novartis

Ketotifen demonstrated significant anti-fibrotic activity in both in vitro and in vivo studies. In TGFβ1-activated human dermal fibroblasts, ketotifen suppressed fibrotic markers like α-smooth muscle actin (αSMA) and reduced cellular contractility. A murine model of bleomycin-induced skin fibrosis supported these findings, showing decreased collagen density and dermal thickness with ketotifen treatment. By targeting fibroblast activation and disrupting pro-fibrotic signaling pathways such as YAP/TAZ and Akt, ketotifen offers promising therapeutic potential for fibrosis-related diseases.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Zaditen 1 by Novartis, consult with your doctor or healthcare professional.